Arcellx (ACLX) Receivables - Accured (2022 - 2025)
Arcellx's quarterly Receivables - Accured came in at $3.6 million in Q4 2025, up 44.0% year-on-year from $2.5 million in Q4 2024, and down 12.2% quarter-over-quarter from $4.1 million in Q3 2025.
Arcellx has reported Receivables - Accured for 4 years, with the latest figure at $3.6 million in Q4 2025.
- For the quarter ending Q4 2025, Receivables - Accured rose 44.0% year-over-year to $3.6 million; the trailing twelve-month figure through Dec 2025 stood at $3.6 million (up 44.0% YoY), and the FY2025 full-year result was $3.6 million, up 44.0% from the prior year.
- Receivables - Accured for Q4 2025 stood at $3.6 million, down from $4.1 million in the prior quarter.
- The five-year high for Receivables - Accured was $4.1 million in Q3 2025, with the low at $500000.0 in Q4 2022.
- Average Receivables - Accured over 4 years is $2.5 million, with a median of $2.9 million recorded in 2025.
- Year-over-year, Receivables - Accured surged 210.0% in 2024 and fell 6.45% in 2025.
- Tracing ACLX's Receivables - Accured over 4 years: stood at $500000.0 in 2022, then soared by 180.0% to $1.4 million in 2023, then surged by 78.57% to $2.5 million in 2024, then soared by 44.0% to $3.6 million in 2025.
- The last three Receivables - Accured figures came in at $3.6 million (Q4 2025), $4.1 million (Q3 2025), and $3.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acc. Int. Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 3.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.60 Mn |
| Dec 31, 2025 | 3.60 Mn |
| Sep 30, 2025 | 4.10 Mn |
| Sep 30, 2025 | 4.10 Mn |
| Jun 30, 2025 | 3.30 Mn |
| Jun 30, 2025 | 3.30 Mn |
| Mar 31, 2025 | 2.90 Mn |
| Mar 31, 2025 | 2.90 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Sep 30, 2024 | 3.40 Mn |
| Sep 30, 2024 | 3.40 Mn |
| Jun 30, 2024 | 3.20 Mn |
| Jun 30, 2024 | 3.20 Mn |
| Mar 31, 2024 | 3.10 Mn |
| Mar 31, 2024 | 3.10 Mn |
| Dec 31, 2023 | 1.40 Mn |
| Dec 31, 2023 | 1.40 Mn |
| Sep 30, 2023 | 1.68 Mn |
| Sep 30, 2023 | 1.68 Mn |
| Jun 30, 2023 | 1.20 Mn |
| Jun 30, 2023 | 1.20 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | 500,000.00 |
| Dec 31, 2022 | 500,000.00 |